{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:44:50Z","timestamp":1766450690644,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.clcc.2020.05.007","type":"journal-article","created":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T02:35:14Z","timestamp":1590719714000},"page":"311-318.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer"],"prefix":"10.1016","volume":"19","author":[{"given":"Silvia","family":"Camera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Am\u00e9lie","family":"Deleporte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Bregni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Trevisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Pretta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugba Akin","family":"Telli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Polastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gombos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Kayumba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieveke","family":"Ameye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Piccart-Gebhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Awada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Sclafani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Hendlisz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2020.05.007_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.clcc.2020.05.007_bib2","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.3390\/cells8091102","article-title":"Trends and challenges in tumor anti-angiogenic therapies","volume":"8","author":"J\u00e1szai","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.clcc.2020.05.007_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clcc.2020.05.007_bib4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1177\/2047487318755193","article-title":"Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer patients","volume":"25","author":"Totzeck","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.clcc.2020.05.007_bib5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","article-title":"Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis","volume":"305","author":"Ranpura","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clcc.2020.05.007_bib6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2011.37.1195","article-title":"Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors","volume":"30","author":"Schutz","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib7","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.05.007_bib8","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib9","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2020.05.007_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesphageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2020.05.007_bib13","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib14","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.05.007_bib16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"Suppl 9","key":"10.1016\/j.clcc.2020.05.007_bib17","first-page":"ix183","article-title":"IMbrave150: efficacy and safety results from a Ph III study evaluating atezolizumab (atezo)\u00a0+ bevacizumab (bev) vs sorafenib (sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma","volume":"30","author":"Cheng","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib18","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2020.05.007_bib20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib21","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clcc.2020.05.007_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.canlet.2008.03.008","article-title":"Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts","volume":"267","author":"Ooyama","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clcc.2020.05.007_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canlet.2014.04.002","article-title":"Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer","volume":"349","author":"Shi","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clcc.2020.05.007_bib24","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3892\/or.2015.3765","article-title":"Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis","volume":"33","author":"Yuan","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.clcc.2020.05.007_bib25","first-page":"E5226","article-title":"Maintenance of antiangiogenic and antitumor effects by orally active low-dose capecitabine for long-term cancer therapy","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clcc.2020.05.007_bib26","doi-asserted-by":"crossref","first-page":"17620","DOI":"10.18632\/oncotarget.24811","article-title":"Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh\/Gr1highmyeloid cells","volume":"9","author":"Iwai","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clcc.2020.05.007_bib27","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1186\/s12885-019-6234-8","article-title":"A\u00a0phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer","volume":"19","author":"Strickler","year":"2019","journal-title":"BMC Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.clcc.2020.05.007_bib28","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0959-8049(17)30306-4","article-title":"A\u00a0phase I\/II dose finding study evaluating the safety and tolerability of capecitabine and aflibercept in patients with unresectable metastatic colorectal cancer deemed unsuitable for doublet\/triplet chemotherapy: results of the phase I study","volume":"72","author":"Ross","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2020.05.007_bib29","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2001.19.3.851","article-title":"Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data","volume":"19","author":"Margolin","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib30","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/sj.bjc.6605663","article-title":"Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer","volume":"102","author":"Feliu","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clcc.2020.05.007_bib31","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","article-title":"TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study","volume":"18","author":"Kuboki","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib33","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","article-title":"Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib34","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1200\/JCO.2005.00.232","article-title":"Combined analysis of efficacy: the addition of bevacizumab to fluorouracil\/leucovorin improves survival for patients with metastatic colorectal cancer","volume":"23","author":"Kabbinavar","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib35","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","article-title":"Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study","volume":"28","author":"Tebbutt","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib36","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib37","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1200\/JCO.2010.33.9101","article-title":"Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer","volume":"29","author":"Stockler","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib38","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1634\/theoncologist.2014-0379","article-title":"Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM\/2009-05): a randomized, noninferiority phase II trial with a pharmacogenetic analysis","volume":"20","author":"Mart\u00edn","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2020.05.007_bib39","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1081\/CNV-200032976","article-title":"Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule","volume":"22","author":"Lokich","year":"2004","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clcc.2020.05.007_bib40","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12032-015-0496-z","article-title":"Continuous, low-dose capecitabine for patients with recurrent colorectal cancer","volume":"32","author":"Romiti","year":"2015","journal-title":"Med Oncol"},{"key":"10.1016\/j.clcc.2020.05.007_bib41","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clcc.2020.05.007_bib42","first-page":"221","article-title":"Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts","volume":"8","author":"Klement","year":"2002","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820300803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002820300803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:07:26Z","timestamp":1761520046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002820300803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1533002820300803"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2020.05.007","relation":{},"ISSN":["1533-0028"],"issn-type":[{"type":"print","value":"1533-0028"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2020.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}